Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

BACKGROUND: Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cytotoxicity represents a major problem during treatment, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Hemant, Göring, Harald H H, Diego, Vincent, Cole, Shelley, Walder, Ken R, Collier, Greg R, Blangero, John, Carless, Melanie A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483163/
https://www.ncbi.nlm.nih.gov/pubmed/22917222
http://dx.doi.org/10.1186/1755-8794-5-37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483163/
https://www.ncbi.nlm.nih.gov/pubmed/22917222
http://dx.doi.org/10.1186/1755-8794-5-37

Ejemplares similares